Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.42 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
| ▸ | TAS1R3 | Q7RTX0 | 4/20 | 0.37 |
| ▸ | TAS1R1 | Q7RTX1 | 4/20 | 0.37 |
| ▸ | HSF1 | Q00613 | 1/20 | 0.37 |
| ▸ | XDH | P47989 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | PPARD | Q03181 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | NAAA | Q02083 | 3/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.35 |
| ▸ | CEPT1 | Q9Y6K0 | 1/20 | 0.35 |
| ▸ | CMA1 | P23946 | 1/20 | 0.34 |
| ▸ | UTRN | P46939 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4046624 | 1.00 | DAGLA (0.42) | DAGLAPDK1PDK2TAS1R3TAS1R1 | |
| SCHEMBL5522116 | 0.91 | DAGLA (0.42) | DAGLATAS1R3TAS1R1HSF1XDH | |
| SCHEMBL5522129 | 0.91 | DAGLA (0.42) | DAGLATAS1R3TAS1R1HSF1XDH | |
| SCHEMBL5519385 | 0.91 | DAGLA (0.43) | DAGLAPDK1PDK2HSF1XDH | |
| SCHEMBL4048197 | 0.91 | DAGLA (0.43) | DAGLAPDK1PDK2HSF1XDH | |
| SCHEMBL5524842 | 0.84 | XDH (0.44) | HSF1XDH | |
| SCHEMBL4049876 | 0.84 | XDH (0.44) | HSF1XDH | |
| SCHEMBL5529494 | 0.82 | DAGLA (0.43) | DAGLAPDK1PDK2HSF1XDH | |
| SCHEMBL4050549 | 0.82 | DAGLA (0.43) | DAGLAPDK1PDK2HSF1XDH | |
| SCHEMBL5523280 | 0.78 | XDH (0.42) | HSF1XDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1744755-B1 | COMPOUNDS AND COMPOSITIONS AS CATHEPSIN S INHIBITORS | IRM LLC (BM) | 2012-12-05 | — | — | EP | claimed |
| US-20070232606-A1 | Compounds and Compositions as Cathepsin S Inhibitors | IRM LLC (BM) | 2007-10-04 | — | — | US | claimed |
| EP-1744755-B1 | COMPOUNDS AND COMPOSITIONS AS CATHEPSIN S INHIBITORS | IRM LLC (BM) | 2012-12-05 | — | — | EP | disclosed |
| US-20070232606-A1 | Compounds and Compositions as Cathepsin S Inhibitors | IRM LLC (BM) | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232606-A1 | Compounds and Compositions as Cathepsin S Inhibitors | CTSS, CTSB, CTSF | DAGLA 2256/4885PDK1 3277/4885PDK2 3864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.